Heterozygous mutations clustered in exon 2 of coiled-coil-helix-coiled-coil-helix domain-containing 10 (*CHCHD10*) have recently been described in clinically heterogeneous neurodegenerative phenotypes including amyotrophic lateral sclerosis (ALS)^[@R1]^ ([figure 1](#F1){ref-type="fig"}). The discovery of mutations in this gene encoding the mitochondrial CHCHD10 protein has lent support to the long-suspected role of mitochondrial dysfunction in the pathogenesis of ALS, but the exact mechanism is uncertain. Recently, we reported that the ALS-causing p.R15L mutation destabilizes the CHCHD10 protein in fibroblasts derived from the carrier, leading to impaired cellular respiration and an increase in the steady-state level of its paralogue CHCHD2 protein.^[@R2]^ The current report is a description of the observed neuropathology from a patient harboring a loss-of-function p.R15L *CHCHD10* mutation.

![Gene structure of CHCHD10\
The upper diagram is the gene structure of *CHCHD10* with 4 coding exons. The lower diagram is the CHCHD10 protein structure (142 amino acid), which includes an MTS (amino acids 1--16), a hydrophobic domain (amino acids 43--68), and a CHCH domain (amino acids 102--133). Mutations that have been described are shown above of the gene structure, and the colored lines indicate the diagnosis of the patient(s) with the reported mutation: ALS (red), ALS-FTD (green), FTD (black), mitochondrial myopathy (blue), Parkinson Disease (pink), Charcot-Marie-Tooth disease (purple), and late-onset spinal motor neuronopathy (orange). ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; MTS = mitochondrial localization signal.](NG2019010306f1){#F1}

Methods {#s1}
=======

The *CHCHD10* p.R15L mutation (rs730880030) in patient with ALS \#8807 (free from mutations in *C9orf72, SOD1*, *GRN*, *FUS*, *MATR3, CHCHD2*, and *TARDBP*) was previously reported as part of a Canadian cohort with neurodegenerative disorders,^[@R3]^ but without clinical details. This patient has now been investigated on a genome-wide exome array tailored to study neurodegenerative diseases (NeuroX; Illumina, San Diego, CA^[@R4]^) for potentially damaging rare variants with a minor allele frequency \<0.1%. Among the detected 63 rare variants, none are known to affect genes implicated in neurodegenerative diseases (table e-1, [links.lww.com/NXG/A219](http://links.lww.com/NXG/A219)).

The patient recently died at age 72 years, he had consented to autopsy, and on his death, a thorough review of his clinical records, and within 6 hours of his death, a postmortem examination limited to the brain and spinal cord were performed. The left cerebral hemisphere, hemi-brainstem, and cerebellum and 3 segments of the spinal cord were fixed in 10% formalin, whereas the remainder of the CNS was frozen. After fixation, the left cerebral hemisphere was sectioned coronally, the hemi-brainstem and spinal cord segments were sectioned axially, the hemi-cerebellum was sectioned sagittally, and a standard neuropathology blocking protocol for ALS was followed. The tissue blocks were cut into 4-μm thick sections, mounted on glass slides, and stained with hematoxylin and eosin/luxol fast blue and immunohistochemistry for TDP43, p62, tau (AT8), beta-amyloid, fused in sarcoma, alpha-synuclein, CHCHD10, and CHCHD2 (detailed immunohistochemical methods are provided in [table 1](#T1){ref-type="table"}). Pertinent microscopic slides were scanned using an Aperio scanner, and digitized photomicrographs were taken.

###### 

Immunohistochemical methods used

![](NG2019010306t1)

In attempts to understand the immunohistochemical staining patterns of CHCHD10 and CHCHD2 in our case, sections from the cervical spinal cord and frontal cortex from 8 other autopsy cases were also stained with these antibodies, including 5 cases of pathologically confirmed ALS and 3 normal controls (additional information is provided in table e-2, [links.lww.com/NXG/A220](http://links.lww.com/NXG/A220)). All the CHCHD10 and CHCHD2 immunostained slides were reviewed blindly and independently by 2 neuropathology assessors (J.L.K. and A.G.).

Sections from the CHCHD10 p.R15L mutation case, 1 sporadic ALS case, and 1 normal control were also examined with immunofluorescence. Formalin-fixed, paraffin-embedded sections through the cervical spinal cord were deparaffinized by placing on a 60°C heat block for 20 minutes and then in xylene (3 × 5 minutes). Rehydration was then performed with sequential graded ethanol washes (100%, 95%, 75%, and 50% wt/vol) before pure water. Heat-induced antigen demasking was completed using Tris-EDTA buffer (10 mM Trizma base, 1 mM EDTA, 0.1% Tween 20, pH 9.0) at 110°C for 15 minutes in a pressure cooker. Blocking was performed with 10% donkey serum (EMD Millipore, Ontario, Canada) and 0.3% TX-100 in tris buffered saline for 1 hour at ambient temperature. Primary antibody incubation was performed overnight at 4°C with anti-rat phosphoTDP43 (Ser409/410) antibody, clone 1D3 (1:1000; Millipore-Sigma, Ontario, Canada, cat\# MABN14), and anti-rabbit CHCHD10 (1:200; Novus Biologicals, Littleton, CO, cat\# NBP1-91169) diluted in DAKO Antibody Diluent (S0809). Processes were labeled separately by pooling anti-mouse nonphosphorylated anti-neurofilament (NF) H (BioLegend, San Diego, CA, cat\# SMI32) and anti-NFH (NF-H; BioLegend, cat\# SMI31) (both 1:500 wt/vol) and paired with anti-rabbit CHCHD10 (1:200; Novus Biologicals, cat\# NBP1-91169) diluted in DAKO Antibody Diluent. After 3 × 20 minute washes in tris buffered saline + 0.1% Tween 20 (tris buffered saline tween), secondary incubation was performed for 1 hour at ambient temperature with either donkey α-rat 488 or donkey α-mouse 488 paired with donkey α-rabbit 594 Alexa Fluor secondary antibodies (Invitrogen, Carlsbad, CA; 1:500) diluted in DAKO Antibody Diluent. Slides were washed 3 × 20 minutes in tris buffered saline tween before mounting with ProLong Gold Antifade reagent with 4′,6-diamidino-2-phenylindole \[DAPI\] (P36931; Life Technologies, Carlsbad, CA). Photomicrographs of the double IF labeling were captured on a Leica DMI6000B microscope with the Volocity Acquisition Suite (v6.3; PerkinElmer, Waltham, MA).

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

This study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre.

Data availability {#s1-2}
-----------------

Access to anonymized data related to the current study will be available from the corresponding author (J.L.K.) on request.

Results {#s2}
=======

The *CHCHD10* p.R15L mutation carrier was Caucasian, without a family history of neurologic disease (mother died at age 77 years of a myocardial infarction, father died suddenly at age 65 years, and 2 siblings are both healthy in their 60s). The patient began manifesting neurologic symptoms at age 54 years with right arm weakness. The weakness involved both arms over the next 2 years and was worse proximally. On examination, the patient initially had exclusively lower motor neuron signs, muscle wasting, and fasciculations in the arms. By age 61 years, the patient developed spastic dysarthria with tongue and perioral fasciculations and lower extremity hyperreflexia with fasciculations and intact power. EMG revealed active and chronic denervation in all segments. An MRI of the cervical spine revealed degenerative changes in the cervical spine without canal or foraminal narrowing to account for the symptoms, and bloodwork was normal including CBC, electrolytes, liver enzymes, ESR, CRP, ANA, RF, serum protein electrophoresis, anti-GM1 antibodies, and West Nile virus serology. Given the presence of lower motor neuron signs in the bulbar, cervical, thoracic, and lumbosacral segments in addition to upper motor neuron signs in the bulbar and lumbosacral segments, the presentation was consistent with clinically probable ALS based on contemporary El Escorial criteria,^[@R5]^ and the patient was started on Riluzole (Rilutek, ATC Code N07X X02). By age 62 years, the patient had dyspnea requiring overnight BiPAP, and by age 69 years, they required BiPAP for most of the day and had upper limb flaccid weakness (1/5 proximally and 4−/5 distally) but retained the ability to walk with mild (4+/5) proximal lower limb weakness. Bulbar and respiratory weakness progressed, and the patient obtained medical assistance in dying at age 72 years. Throughout their disease course, the patient never demonstrated cognitive, affective, or personality changes, although formal neuropsychological testing was not performed.

On neuropathologic macroscopic examination, the fresh brain weight was 1,560 g, the cerebral gyri were a normal caliber externally, and coronal sections through the left hemisphere showed no abnormalities of the cerebral cortex, white matter, and mesial temporal or deep gray structures. Axial sections through the brainstem were unremarkable. The anterior spinal nerve roots were thin and pale, and axial sections through the spinal cord appeared otherwise normal.

On microscopic examination, there were findings typical of ALS within the spinal cord and brainstem as shown in [figure 2](#F2){ref-type="fig"}. At all levels of the spinal cord, there was mild degeneration of the lateral corticospinal tract ([figure 2A](#F2){ref-type="fig"}). There was severe loss of motor neurons and gliosis within the anterior horns ([figure 2B](#F2){ref-type="fig"}), more pronounced in the cervical levels, with rare cytoplasmic eosinophilic p62 immunopositive inclusions in remaining motor neurons, the morphology of which ranged from ill-defined faintly eosinophilic structures to large, densely eosinophilic round structures reminiscent of corpora amylacea. There were no neuronal inclusions present that immunolabeled with TDP43 ([figure 2C](#F2){ref-type="fig"}), fused in sarcoma, tau (AT8), or alpha-synuclein. No Bunina bodies were seen. There was also severe neuronal loss and gliosis within the hypoglossal nucleus ([figure 2D](#F2){ref-type="fig"}) without p62 or TDP43 immunopositive inclusions.

![Predominantly lower motor neuron degeneration within the spinal cord and brainstem of CHCHD10 mutated amyotrophic lateral sclerosis case\
(A) Hematoxylin and eosin (H&E)/LFB-stained section of the cervical spinal cord showing mild bilateral degeneration of the lateral corticospinal tracts (black arrows) and thin and pale anterior spinal nerve roots on myelin staining (green arrowheads) in comparison to the posterior spinal nerve roots. (B and C) H&E/LFB and TDP43 staining of the anterior horn of the cervical spinal cord (area depicted in black box in [figure 1A](#F1){ref-type="fig"}) showing severe neuronal loss and gliosis without TDP43 immunopositive inclusions in remaining motor neurons. (D) H&E-stained section of the medullary tegmentum showing severe neuronal loss and gliosis within the hypoglossal nucleus (black ellipse). (E and F) Normal population and morphology of Betz neurons in the motor cortex, which do not contain TDP43-positive inclusions. Scale bar = 3 mm (A), 200 μm (B and C), 300 μm (D), and 100 μm (E and F). LFB = luxol fast blue.](NG2019010306f2){#F2}

Other findings in the brainstem included scattered long thin p62 immunopositive neurites throughout the medullary tegmentum and olivary nuclei, a normal population of pigmented neurons within the substantia nigra without Lewy bodies, rare nigral neurons contained filamentous cytoplasmic TDP43 immunopositive inclusions, and the remainder of the brainstem was unremarkable including the motor nuclei of cranial nerve V, VI, and VII.

Cortical sections showed a relatively normal complement of Betz motor neurons ([figure 2E](#F2){ref-type="fig"}) without p62/TDP43 immunopositive inclusions within the primary motor cortex ([figure 2F](#F2){ref-type="fig"}). There was no significant atrophy of the frontal or temporal cortex. Only rare p62 immunopositive long thin neurites and neuronal cytoplasmic inclusions were seen in the superficial layers of the frontal cortex. No cortical amyloid plaques or neurofibrillary tangles were present. The mesial temporal structures showed mild gliosis of the endplate and CA1, but there was no mesial temporal sclerosis and no p62/TDP43-positive inclusions were present. Sections treated with tau (AT8) immunohistochemistry highlighted (+) neurofibrillary tangles within CA1 and (++) neurofibrillary tangles within the superficial layers of the entorhinal cortex, corresponding to mild primary age-related tauopathy. There was no alpha-synuclein pathology. The deep gray nuclei, cerebellar cortex, and dentate nuclei appeared normal.

The results of CHCHD2 and CHCHD10 immunohistochemistry are shown in [figure 3](#F3){ref-type="fig"} and figure e-1 ([links.lww.com/NXG/A218](http://links.lww.com/NXG/A218)). The CHCHD2 immunolabeling was comparable between the *CHCHD10* mutated ALS case, normal controls, and sporadic ALS; all showed strong neuronal, glial, and endothelial cytoplasmic labeling in gray and white matter within the spinal cord ([figure 3, A--C](#F3){ref-type="fig"}) and cerebral cortex. CHCHD10 immunohistochemistry was comparable for the normal controls and sporadic ALS, all showing strong neuronal cytoplasmic and axonal labeling ([figure 3D](#F3){ref-type="fig"}). The *CHCHD10* mutated ALS case showed a different pattern of CHCHD10 labeling; in addition to the strong neuronal cytoplasmic and axonal staining seen in the other cases, there were also numerous aggregates of CHCHD10 within the anterior horns, slightly more abundant at cervical levels ([figure 3, E--G](#F3){ref-type="fig"}, figure e-1, A--C, [links.lww.com/NXG/A218](http://links.lww.com/NXG/A218)). These aggregates had a dense central core and a surrounding halo of CHCHD10 immunopositivity ([figure 3, H and I](#F3){ref-type="fig"}), and they did not contain CHCHD2. Also present were rare corkscrew-shaped CHCHD10 immunopositive inclusions within all levels of the anterior horn ([figure 3, F and J](#F3){ref-type="fig"}). The frontal cortex of the CHCHD10 mutated case showed predominantly strong neuronal cytoplasmic and axonal labeling with CHCHD10, but CHCHD10 aggregates and corkscrew-shaped inclusions were also present focally in the superficial cortical layers (figure e-1, D--F).

![CHCHD2 and CHCHD10 immunohistochemical labeling of the spinal cord\
(A--C) CHCHD2 immunolabeling in the spinal cord of normal control (A), sporadic amyotrophic lateral sclerosis (ALS) (B), and CHCHD10 mutated ALS (C), all showing strong neuronal, glial, and endothelial cytoplasmic labeling in gray and white matter. (D) CHCHD10 immunolabeling in the normal control spinal cord showing strong neuronal, glial, and endothelial cytoplasmic labeling, which was comparable to sporadic ALS cases. (E--I) CHCHD10 immunolabeling of the spinal cord of CHCHD10 mutated ALS showing that in addition to the strong neuronal cytoplasmic labeling comparable to control cases and sporadic ALS cases, there are numerous aggregates of CHCHD10 within the anterior horn (arrows in F and G. Aggregates indicated by black arrows in G are shown in H and I). There are also occasional corkscrew-shaped inclusions (red arrow in F, higher magnification of this inclusion shown in J). Scale bar = 300 μm (A), 200 μm (B--D, F, and G), 500 μm (E).](NG2019010306f3){#F3}

The results of double immunofluorescence immunolabeling for CHCHD10 and TDP43 and for CHCHD10 and NF are shown in [figure 4](#F4){ref-type="fig"}. In the sporadic ALS case, TDP43-positive filamentous neuronal cytoplasmic inclusions were seen within anterior horn motor neurons ([figure 4A](#F4){ref-type="fig"}, green). There was faint neuronal cytoplasmic expression of CHCHD10 within all motor neurons ([figure 4A](#F4){ref-type="fig"}, red), but the TDP43-positive inclusions did not colabel with CHCHD10. In comparison, the *CHCHD10* mutated ALS case contained many corkscrew-shaped CHCHD10-positive structures within the anterior horn, and these CHCHD10 aggregates did not colabel with TDP43 ([figure 4B](#F4){ref-type="fig"}). Double immunolabeling for CHCHD10 and NF in the normal control case confirmed cytoplasmic immunolabeling for CHCHD10 within the anterior horn motor neurons and also showed many small, CHCHD10-positive neurites in the background ([figure 4C](#F4){ref-type="fig"}, CHCHD10 in red and NF in green). In the anterior horns of the *CHCHD10* mutated ALS case, the vast majority of CHCHD10 aggregates appeared to be corkscrew shaped and extracellular, as they had no associated NF immunolabeling ([figure 4, D, G, and H](#F4){ref-type="fig"}). However, very rare CHCHD10 neuronal cytoplasmic inclusions were also seen ([figure 4D](#F4){ref-type="fig"}), and rare examples of CHCHD10 labeling were seen surrounded by a thin rim of NF, which suggests that some CHCHD10 inclusions may be within neuronal cell processes.

![CHCHD10 labeling does not overlap with TDP43 pathology in the spinal cord\
(A and B) Immunofluorescence overlay of CHCHD10 (red), phosphorylated TDP43 (green), and DAPI (blue) in the spinal cord of sporadic amyotrophic lateral sclerosis (ALS) (A) and CHCHD10 mutated ALS (B); arrows = TDP43 pathology; arrowheads = aggregated CHCHD10; asterisk = lipofuscin. (C--H) Overlay of CHCHD10 (red) and both nonphosphorylated/phosphorylated neurofilament H (NF-H; green) in normal control (C) and mutated CHCHD10 (D--H); arrows = aggregated CHCHD10 surrounded by NF-H; arrowheads = extracellular CHCHD10 aggregates. Scale bar = 20 μm (A and B); 30 μm (C and D); and 10 μm (E--H). DAPI = 4\',6-diamidino-2-phenylindole.](NG2019010306f4){#F4}

Discussion {#s3}
==========

The CHCHD10 protein is in the mitochondrial intermembrane space, enriched in mitochondrial cristae junctions.^[@R1]^ The exact function of the CHCHD10 protein continues to be elucidated, but it may alter fragmentation of mitochondria, increase instability of mitochondrial DNA, and decrease mitochondrial complex-IV activity.^[@R1],[@R6]^ CHCHD10 forms part of the multiprotein complex MICOS, which plays a vital role in the formation and maintenance of cristae structure.^[@R7]^ A recent study^[@R8]^ demonstrated that CHCHD10 is a regulator of mitochondrial respiration and can contribute to transcriptional repression of oxygen-responsive element containing genes, and some genetic *CHCHD10* variants (G66V and P80L) are impaired in these activities.

Patients with *CHCHD10* mutations have a broad clinical phenotypic range ([figure 1](#F1){ref-type="fig"}), including ALS/frontotemporal dementia (FTD),^[@R1],[@R9]^ ALS,^[@R3],[@R10],[@R11]^ FTD,^[@R3]^ mitochondrial myopathy,^[@R6],[@R12]^ ataxia,^[@R13]^ parkinsonism,^[@R14]^ axonal Charcot-Marie-Tooth disease,^[@R15]^ and Jokela type spinal muscular atrophy.^[@R16]^ All pathogenic *CHCHD10* mutations are missense substitutions except for a stop-gain mutation (p.Q82X) suggesting a loss-of-function mechanism.

The collective understanding of *CHCHD10* mutations in ALS began in 2014^[@R1]^ when a p.S59L mutation was identified in 8 affected members of a French family with autosomal dominant ALS/FTD using whole-exome sequencing. In 8 affected members of a large French family with autosomal dominant frontotemporal dementia and/or amyotrophic lateral sclerosis-2 (FTDALS2; 615903.0001), Bannwarth et al.^1^ identified a homozygous c.176C-T transition in exon 2 of the CHCHD10 gene, resulting in a ser59-to-leu (S59L) substitution at a highly conserved residue in the hydrophobic N-terminal alpha-helix. The mutation, which was found by whole-exome sequencing, segregated with the disorder in the family and was not present in the dbSNP (build 132), Exome Variant Server, or 1000 Genomes Project database, in in-house control exomes, or in 200 matched control alleles. The mutation, which was found by whole-exome sequencing, segregated with the disorder in the family and was not present in the dbSNP (build 132), Exome Variant Server, or 1000 Genomes Project database, in in-house control exomes, or in 200 matched control alleles. Genome sequencing of an ALS data set^[@R10]^ identified a large family segregating the p.R15L *CHCHD10* substitution in 4 affected individuals, and the follow-up Sanger sequencing of *CHCHD10* in 84 patients with familial ALS found the same mutation in 2 more patients. All 6 patients carrying the p.R15L variant shared a 6.2 Mb haplotype across the *CHCHD10* gene^[@R10],[@R11]^ also reported the p.R15L mutation in 2 unrelated German ALS families with an autosomal dominant mode of inheritance but incomplete penetrance. The presence of unaffected p.R15L carriers among family members provoked discussion of whether p.R15L is truly pathogenic.^[@R17]^ However, segregation of p.R15L with disease could be masked by the complexity of *CHCHD10*-related subphenotypes, late age at onset, and slow disease progression, as observed in our case.^[@R3],[@R11]^ Recently, the MinE ALS consortium whole genome sequenced 4,365 patients with ALS and 1,832 controls^[@R18]^ and reported that *CHCHD10* mutations are less prevalent in pure ALS than originally suggested. They reported 3 new variants (1 ALS specific and 1 control specific), and there was no increased burden of *CHCHD10* mutations among patients with ALS compared with controls. The few carriers with potentially pathogenic *CHCHD10* mutations exhibited a slowly progressive ALS-like phenotype with atypical features including myopathy and deafness.

Importantly, functional studies support the pathogenic role of the p.R15L mutation. The study of fibroblasts derived from the p.R15L carrier revealed a 2-fold reduction in CHCHD10, a 2.5-fold increase in CHCHD2, a 2-fold decrease in complex I, a reduction in the amount of oxygen consumption, and an increase in anaerobic glycolysis when compared with a noncarrier.^[@R2]^ Furthermore, *C. elegans* deficient in *har-1* (orthologue to human *CHCHD10*) display locomotion abnormalities and reduced lifespan associated with mitochondrial superoxide overproduction, which were rescued by wild-type CHCHD10 but not *CHCHD10* with p.R15L or p.S59L mutations.^[@R19]^ In mammalian cells, overexpression of both *CHCHD10* mutations exhibited abnormal mitochondrial phenotypes and reduced pre/postsynaptic integrity.^[@R19]^ Finally, the pathogenic nature of p.R15L is further supported by its absence in the Healthy Exomes database that contains sequencing results from ∼500 controls older than 60 years who had no neurodegenerative neuropathology ([alzforum.org/exomes/hex](https://www.alzforum.org/exomes/hex)).

By what mechanism could a *CHCHD10* mutation induce an ALS phenotype? Mitochondrial dysfunction and oxidative stress are known to contribute to neurodegeneration and cellular aging,^[@R20]^ and pathogenic mitochondria-related proteins have been identified in many neurodegenerative conditions.^[@R20],[@R21]^ The discovery of mutations in *CHCHD10* has lent support to the long-suspected role of mitochondrial dysfunction in the pathogenesis of ALS; previously, there have been few reported mutations in genes encoding bona fide mitochondrial proteins in the context of ALS. Intriguingly, several lines of evidence suggest a functional link between CHCHD10 and TDP43. For instance, the neurotoxicity of TDP43 may be mediated by mitochondrial dysfunction^[@R22][@R23][@R24]^; the role of mitochondrial dysfunction, morphology, fission/fusion dynamics, distribution, and trafficking in ALS has been reviewed.^[@R25]^ Recent cell culture and animal model studies have shown that TDP43 interacts with CHCHD10 and promotes its nuclear localization.^[@R19]^ Specifically, *CHCHD10* mutations (p.R15L and p.S59L) exhibit dominant negative activities in mammalian systems, resulting in mitochondrial/synaptic damage and cytoplasmic TDP43 accumulation. A recent fibroblast culture study demonstrated that the cellular phenotypes of specific *CHCHD10* mutations differ and that loss of MICOS complex integrity and mitochondrial dysfunction, but not TDP43 mitochondrial localization, may be required to develop a severe motor neuron disease phenotype.^[@R26]^

The present report is a neuropathologic description of a rare ALS case with a pathogenic *CHCHD10* mutation. We have observed in the present case some of the classic histopathologic findings of ALS, namely severe loss of lower motor neurons of the spinal cord and hypoglossal nucleus and mild corticospinal tract degeneration. The burden of our patient\'s disease being primarily lower motor neuron and in the cervical spinal cord correlates well with his clinical symptoms including arm weakness at onset followed by the development of lower motor neuron signs in the bulbar and cervical, thoracic, and lumbosacral segments and upper motor neuron signs in the bulbar and lumbosacral regions. The absence of coexisting FTLD correlates well with his intact cognition and absent behavioral symptoms. Some of the observed pathology in our case is somewhat unexpected, including the lack of TDP43 motor neuron immunopathology, given both the presence of TDP43 immunopathology in the vast majority of ALS cases and the suggested functional links between CHCHD10 and TDP43. Double immunofluorescence labeling clearly showed that the observed CHCHD10 aggregates did not colocalize with TDP43. The absence of Lewy body pathology, nigral degeneration, and cerebellar pathology is pertinent, given the previous descriptions of parkinsonism and ataxia in the presence of *CHCHD10* mutations, and our case showed neither the focal "ischemic-like" lesions nor diffuse neuronal or white matter loss that has been described in the CNS of patients with mitochondriopathies.

The literature contains minimal information about the pattern of CHCHD2 and CHCHD10 immunostaining within the human nervous system in its normal state or in the setting of neurodegenerative disease such as ALS. According to the Human Protein Atlas ([proteinatlas.org/ENSG00000250479-CHCHD10/antibody\#immunocytochemistry](https://www.proteinatlas.org/ENSG00000250479-CHCHD10/antibody)), the distribution of CHCHD10 immunohistochemical staining is consistent with RNA expression levels across 36 tissues. There is a recent description of a Parkinson disease case, Lewy body dementia case, and ALS/FTD case in which CHCHD2 and CHCHD10 immunostaining showed strong neuronal staining in the substantia nigra and cortex and hippocampus, respectively; the authors suggest that CHCHD2 and CHCHD10 are highly coexpressed in the affected cell types in these conditions.^[@R27]^

Animal models have shown CHCHD10 to be highly expressed in the motor neurons of the spinal cord, and both knock-out and knock-in *CHCHD10* mutant mouse models have been created.*^[@R28]^ CHCHD10^S55L^* knock-in mice, which mimic the human p.S59L mutation, exhibit late-onset progressive motor deficits and early mortality. These mice have been shown to house aggregates of CHCHD10 and CHCHD2 in their affected tissues, including the spinal cord, by filter trap assay. These aggregates trigger a mitochondrial integrated stress response and may be linked to mitochondrial degeneration and disease in a tissue selective fashion.^[@R28]^ The aggregates of CHCHD10 seen in our patient\'s anterior horns could represent a histologic correlate of the CHCHD10 aggregates described in the CHCHD10^855L^ mouse model; however, our patient\'s *CHCHD10* mutation was a loss of function p.R15L mutation. The mouse model did not have anterior horn motor neuron loss leading to speculation that the motor symptoms in the setting of a *CHCHD10* mutation may result from motor peripheral neuropathy.^[@R28]^ Our findings dispute this suggestion, as our patient had severe loss of anterior horn and hypoglossal motor neurons.

The cellular location of the CHCHD10 aggregates we describe on immunohistochemistry and immunofluorescence is interesting; the fact that occasional aggregates are surrounded by NF may suggest that these aggregates are originally developing within neuronal cell processes. The vast majority of CHCHD10 aggregates were not surrounded by NF, however, which may indicate that after the death of the parent neuron, the remaining aggregates have an extracellular location.

Overall, this study describes the neuropathology and unique CHCHD10 immunostaining pattern in a patient with ALS due to *CHCHD10* p.R15L mutation and sheds further light on recently reported findings from an animal model.
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